Nektar Therapeutics
NKTR
$56.90
-$2.02-3.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.84% | -64.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.84% | -64.15% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 6.84% | -50.66% | |||
| SG&A Expenses | -29.88% | 42.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.35% | 1.80% | |||
| Operating Income | 19.35% | -79.75% | |||
| Income Before Tax | 17.80% | -825.94% | |||
| Income Tax Expenses | -461.54% | 120.08% | |||
| Earnings from Continuing Operations | 18.26% | -800.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.26% | -800.76% | |||
| EBIT | 19.35% | -79.75% | |||
| EBITDA | 19.05% | -80.45% | |||
| EPS Basic | 18.41% | -796.80% | |||
| Normalized Basic EPS | 18.56% | -57.29% | |||
| EPS Diluted | 18.41% | -809.65% | |||
| Normalized Diluted EPS | 18.56% | -60.17% | |||
| Average Basic Shares Outstanding | 0.18% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.18% | -1.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||